• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Doctors, Data, and Drug Development

Article

Pharmaceutical Executive

It is estimated that applying big data strategies could potentially generate up to $100 billion in value annually across the US healthcare systems, specifically by optimizing innovation and improving the efficiency of research and clinical trials.

It is estimated that applying big data strategies could potentially generate up to $100 billion in value annually across the US healthcare systems, specifically by optimizing innovation and improving the efficiency of research and clinical trials.

With the advent of global CROs entering into the capital intensive sector of healthcare reimbursements, supporting pharmaceutical and biotech companies to formulate their reimbursement strategy, it is only a natural course of evolution for them to be more data-driven and focused, thereby creating value for the drug product they are developing as early as they could.

In this Applied Clinical Trials article, Uma Arumugam assesses one such data visualisation tool from a doctor’s perspective.

Recent Videos
Related Content